In adults with type 2 diabetes, the drugs lixisenatide and exenatide do not lower the rate of serious heart problems more than a placebo, based on combined results from multiple clinical trials.
Mechanism
Synthesis from 1 study
These drugs lower blood sugar but don't change how dangerous plaques in arteries behave or how the heart handles low oxygen. Because the heart and blood vessels aren't protected at the level of structure or function, the risk of heart attacks and strokes stays the same as with no drug.
Most probable mechanism
The drugs activate a receptor that affects blood sugar but do not change how fatty deposits in arteries behave or how the heart responds to low oxygen, so the risk of heart attacks and strokes stays the same as with no treatment.
GLP-1 receptor agonists increase insulin secretion and suppress glucagon release, lowering blood glucose levels without altering systemic inflammation or endothelial dysfunction
Reduced hyperglycemia does not translate to decreased oxidative stress in vascular endothelium or reduced macrophage infiltration into atherosclerotic lesions
No measurable change occurs in plaque composition, fibrous cap thickness, or coronary artery vasomotor tone during ischemic stress
Myocardial oxygen demand and supply remain unaltered during acute cardiovascular events, with no shift in arrhythmia thresholds or infarct size
Evidence from Studies
Supporting (1)
Community contributions welcome
Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.